This site is intended for health professionals only

Published on 26 April 2012

Share this story:

CHMP refuses Folotyn after re-application


The Committee for Medicine Products for Human Use (CHMP) has refused, on re-examination of Allos Therapeutics Limited’s application, to recommend marketing authorisation for Folotyn (pralatrexate) for treatment of peripheral T-cell lymphoma. 


This follows its adoption of a negative opinion on 19 January 2012, when it recommended refusal of marketing authorisation for Folotyn for peripheral T-cell lymphoma.


Folotyn contains the active substance pralatrexate, and it was intended to be available as a solution for infusion. 

Folotyn was designated an ‘orphan medicine’, for use in rare diseases, 13 April 2007.

European Medicines Agency

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine